The psychedelic sector never sits still. Here is what happened during the week of February 16–22, 2026, and why each story matters for the companies and investors we track.
Compass Pathways plc (CMPS): Compass hits primary endpoint in second Phase 3 psilocybin trial, giving it two positive pivotal studies
Compass Pathways announced that its Phase 3 COMP006 trial met its primary endpoint, with two fixed 25 mg doses of COMP360 psilocybin showing a highly statistically significant MADRS reduction versus a 1 mg comparator (difference of -3.8 points, p<0.001) at the Week 6 endpoint. The company also released 26-week durability data from its first Phase 3 (COMP005), making COMP360 the first psilocybin therapy with two positive pivotal readouts in treatment-resistant depression. Compass reiterated plans to complete a rolling NDA submission in Q4 2026, and psychedelic stocks broadly rallied on the news.
Source: businesswire.com
Compass Pathways plc (CMPS): Compass prices $150 million public offering on the heels of Phase 3 data
Capitalizing on its positive Phase 3 readouts, Compass priced a public offering of 17.5 million American Depositary Shares at $8.00 each, plus pre-funded warrants, for expected gross proceeds of about $150 million (before a 30-day over-allotment option for up to ~2.8 million more ADSs). Proceeds are earmarked for its ongoing COMP005/COMP006 trials, a Phase 2b/3 PTSD study, and commercial-readiness activities. The raise strengthened Compass's balance sheet ahead of its planned regulatory filing.
Source: businesswire.com
That's the recap. Follow the Psychedelic Invest Index for how the sector is trading, and check back next week for the next edition.